J Jiang1, Y-Q Chen, Y-K Zhu, X-H Yao, J Qi. 1. Department of Ultrasound, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Abstract
OBJECTIVES: This study was designed to identify factors that influenced the degree of enhancement of prostate cancer on contrast-enhanced transrectal ultrasonography (CETRUS). METHODS: 139 patients suspected of prostate cancer were evaluated with CETRUS followed by systematic and targeted transrectal ultrasound-guided biopsies. The degree of enhancement of the lesions was objectively measured using peak intensity with time-intensity curve analysis software. Ultrasound findings were correlated with clinical characteristics as well as biopsy and radical prostatectomy findings. RESULTS: Prostate cancers were detected in 230 biopsy sites from 91 patients. The mean peak intensity value of prostate cancer was significantly higher than that of the benign lesions (9.82 ± 3.73 vs 7.51 ± 2.97; p<0.001), and the peak intensity value of the cancer foci varied across the prostate. The mixed model analysis revealed that the location and Gleason score of tumour foci were the influencing factors of the peak intensity value, and the former had a stronger influence upon peak intensity than the latter (p=0.000 and 0.040, respectively). However, age, prostate volume or serum prostate-specific antigen of the patient had no significant influence on the peak intensity value (p>0.05). Furthermore, the peak intensity value of tumours larger than 5 mm diameter was significantly higher than tumours of 5 mm or smaller diameter (9.28 ± 2.46 vs 6.69 ± 2.65; p<0.001). CONCLUSIONS: The prostate cancer lesions with a higher Gleason score and larger tumour size which were located in the lateral peripheral zone (PZ) were more likely to show a marked enhancement. Lesions with lower peak intensity that are located in the medial PZ should also be treated as suspicious.
OBJECTIVES: This study was designed to identify factors that influenced the degree of enhancement of prostate cancer on contrast-enhanced transrectal ultrasonography (CETRUS). METHODS: 139 patients suspected of prostate cancer were evaluated with CETRUS followed by systematic and targeted transrectal ultrasound-guided biopsies. The degree of enhancement of the lesions was objectively measured using peak intensity with time-intensity curve analysis software. Ultrasound findings were correlated with clinical characteristics as well as biopsy and radical prostatectomy findings. RESULTS:Prostate cancers were detected in 230 biopsy sites from 91 patients. The mean peak intensity value of prostate cancer was significantly higher than that of the benign lesions (9.82 ± 3.73 vs 7.51 ± 2.97; p<0.001), and the peak intensity value of the cancer foci varied across the prostate. The mixed model analysis revealed that the location and Gleason score of tumour foci were the influencing factors of the peak intensity value, and the former had a stronger influence upon peak intensity than the latter (p=0.000 and 0.040, respectively). However, age, prostate volume or serum prostate-specific antigen of the patient had no significant influence on the peak intensity value (p>0.05). Furthermore, the peak intensity value of tumours larger than 5 mm diameter was significantly higher than tumours of 5 mm or smaller diameter (9.28 ± 2.46 vs 6.69 ± 2.65; p<0.001). CONCLUSIONS: The prostate cancer lesions with a higher Gleason score and larger tumour size which were located in the lateral peripheral zone (PZ) were more likely to show a marked enhancement. Lesions with lower peak intensity that are located in the medial PZ should also be treated as suspicious.
Authors: Friedrich Aigner; Michael Mitterberger; Peter Rehder; Leo Pallwein; Daniel Junker; Wolfgang Horninger; Ferdinand Frauscher Journal: J Endourol Date: 2010-05 Impact factor: 2.942
Authors: Michael Mitterberger; Wolfgang Horninger; Friedrich Aigner; Germar M Pinggera; Ilona Steppan; Peter Rehder; Ferdinand Frauscher Journal: Cancer Imaging Date: 2010-03-03 Impact factor: 3.909
Authors: M Mitterberger; G M Pinggera; W Horninger; G Bartsch; H Strasser; G Schäfer; A Brunner; Ethan J Halpern; J Gradl; L Pallwein; F Frauscher Journal: J Urol Date: 2007-06-11 Impact factor: 7.450
Authors: Michael Mitterberger; Wolfgang Horninger; Alexandre Pelzer; Hannes Strasser; Georg Bartsch; Patrizia Moser; Ethan J Halpern; Johann Gradl; Friedrich Aigner; Leo Pallwein; Ferdinand Frauscher Journal: Prostate Date: 2007-10-01 Impact factor: 4.104
Authors: Leo Pallwein; Michael Mitterberger; Alexandre Pelzer; Georg Bartsch; Hannes Strasser; Germar M Pinggera; Friedrich Aigner; Johann Gradl; Dieter Zur Nedden; Ferdinand Frauscher Journal: Eur Radiol Date: 2007-10-16 Impact factor: 5.315
Authors: Michael Seitz; Christian Gratzke; Boris Schlenker; Alexander Buchner; Alexander Karl; Alexander Roosen; Bernhard B Singer; Patrick J Bastian; Süleyman Ergün; Christian G Stief; Oliver Reich; Derya Tilki Journal: Urol Oncol Date: 2009-06-12 Impact factor: 3.498